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Heart valve disease is unique in that it aﬀects both the very young and very old, and does not discriminate by ﬁnancial aﬄuence,
social stratus, or global location. Research over the past decade has transformed our understanding of heart valve cell biology,
yet still more remains unclear regarding how these cells respond and adapt to their local microenvironment. Recent studies have
identiﬁed inﬂammatory signaling at nearly every point in the life cycle of heart valves, yet its role at each stage is unclear. While
the vast majority of evidence points to inﬂammation as mediating pathological valve remodeling and eventual destruction, some
studies suggest inﬂammation may provide key signals guiding transient adaptive remodeling. Though the mechanisms are far
from clear, inﬂammatory signaling may be a previously unrecognized ally in the quest for controlled rapid tissue remodeling, a key
requirement for regenerative medicine approaches for heart valve disease. This paper summarizes the current state of knowledge
regarding inﬂammatory mediation of heart valve remodeling and suggests key questions moving forward.
1.Introduction
The heart valves are the sole mediators of unidirectional
ﬂow through the cardiovascular system. These valves ﬂex
open and close 30 million times per year, subjecting the
thin and ﬂexible cusps or leaﬂets to demanding tissue
strains and hemodynamic stresses. The fact that these tissues
thrive can only be attributed to the remarkable stamina
and remodeling capacity of the indigenous valve endothelial
and interstitial cells that populate these valves. Over the
past decade, many exciting discoveries have been made
regarding the unique phenotypes of these cells, yet it has
only framed the beginning of our understanding of valve
function and dysfunction. Heart valve disease remains a
seriousandincreasingclinicalproblemforwhichnosolution
exists save prosthetic replacement. These come in the form
of mechanical or processed biological tissue valves. While
providing over 20 years of function in elderly patients,
these technologies perform dismally in children and young
adults, with undesirable lifestyle restrictions and signiﬁcant
medical requirements. Tissue engineering has the potential
to alleviate these limitations by providing a living valve
conduit that can grow and remodel with the patient. Current
results in animal trials are very promising, but human trials
to date suggest that there is still much more to learn.
Foremost among these needs is to understand how valve
tissue remodels in the midst of the complex mechanical
and biological signaling environment in which it resides.
This includes natural tissue remodeling that occurs over
embryonic development into adulthood, homeostatic and
pathological adaptation over the course of life and disease,
and with diﬀerent living tissue replacement strategies. Being
a biological structure that evolves and adapts over the entire
lifespan, it seems likely that similar signaling mechanisms
would be utilized across this continuum. While literally
hundreds of regulatory genes have been identiﬁed in valve
phenotypes and discussed in several reviews, this review will
focus on the role of inﬂammation. While it is well appreci-
ated that inﬂammation is a major driver of valve pathology,
recent evidence suggests that inﬂammatory cytokines are
presentinembryonicdevelopmentandinremodelingvalves,
which suggests its presence may not be singularly negative.2 International Journal of Inﬂammation
2. Inﬂammationand Wound Healing
The general healing response to tissue injury involves three
phases: inﬂammation, tissue formation, and tissue remod-
eling [1]. The healing response begins when the tissue is
injured, blood comes into contact with collage or other com-
ponents of the extracellular matrix, and a blood clot forms.
The blood clot platelets release chemotactic factors that
recruit leukocytes to the injury site and initiate the inﬂam-
mation phase [2]. These leukocytes then secrete chemokines
and inﬂammatory cytokines to enhance the inﬂammatory
response [2]. Next, neutrophils enter the wound site to
remove foreign materials, bacteria, and damaged tissue;
macrophages follow to continue the process of phagocytosis
[3]. Fibroblasts deposit new extracellular matrix in the tissue
formation phase [3]. In the remodeling phase, the newly
deposited extracellular matrix is cross-linked and organized
[3]. There are many cell signaling events required for this
tightly controlled repair process to take place. The cytokine
transforming growth factor-β (TGF-β) has been shown to
play a part in all three phases of healing [4].
The inﬂammatory phase is initiated when TGFβ and
othergrowthfactorsarereleasedfromplatelets[5].TGFβhas
beenshowntobechemotacticandmitogenicforneutrophils,
lymphocytes, monocytes, macrophages, and ﬁbroblasts [6].
During the tissue formation phase inﬂammatory cells
migrate to the wound and secrete additional TGFβ,w h i c h
at higher concentrations may induce the expression of
other growth factors and increase cell proliferation at the
wound site, stimulate angiogenesis, and promote collagen
deposition [6–8]. During tissue remodeling TGFβ continues
to promote extracellular matrix production and inhibit its
breakdown, which has been implicated the cytokine in scar
formation [6, 9]. Scars are ﬁbrous tumors characterized
by overabundant collagen deposition [10]. Treatment with
TGFβ hasbeenshowntoincreaseendogenousTGFβ produc-
tion,collagendeposition,andscarformation;whileexposure
to anti-TGFβ antibody decreases endogenous TGFβ produc-
tion, collagen deposition, and scarring [9–11].
3. Inﬂammationand ValveHomeostasis
Each valve is comprised of thin, ﬁbrous leaﬂets or cusps that
are attached to a relatively rigid annulus or root [12]. The
atrioventricular valves are further supported by tendinous
chords that connect the leaﬂet free edge to the papillary
muscles [12]. The leaﬂets/cusps are a multilayer composite
of collagen, elastin, and glycosaminoglycans that assist in
its eﬃcient biomechanical function [12]. The surfaces of
these tissues are lined with endothelial cells (VEC) while
the underlying matrix is populated with interstitial cells
(VIC)—a constellation of subphenotypes with incompletely
understood individual roles [13]. In general, the endothelial
cells are responsible for sensing and integrating biological
and mechanical signals from the blood, and transmitting
signals to the interstitial cells [14]. The VIC in turn
proliferate and remodel the surrounding matrix [15]. Both
celltypesarealsoaﬀectedbyothermicroenvironmentalcues,
such as mechanical strain, tissue stiﬀness, and the presence
of other cell types such as inﬂammatory macrophages and
circulating cells [16]. Mitral valve cell biology is much less
understood because the tissue is much more heterogeneous
in structure and composition, potentially reﬂective of its
more diverse mechanical environment [17]. The mitral valve
is unsurprisingly susceptible to a much wider range of
dysfunctional conditions (explained later). Therefore, this
section will discuss results from aortic valves.
The inﬂow (atrialis/ventricularis) surface is exposed to
a rapid, pulsatile, unidirectional shear stress with cycle
averaged magnitude of 20dynes/cm2 [18]. The outﬂow
(ﬁbrosa) surface experiences a much lower magnitude,
nearly oscillatory shear stress [19]. VEC align perpendicular
to the direction of ﬂow in vitro and in vivo whereas vascular
EC align parallel [20]. Microarray comparisons between
aorticvalvularandvascularendotheliuminstaticcultureand
under ﬂuid ﬂow identify hundreds of signiﬁcantly diﬀerent
genes, suggesting that VEC are a distinct endothelial phe-
notype [21]. Steady shear stress was protective against pro-
oxidation and proinﬂammation in both cell types, but VEC
were inherently less inﬂammatory than arterial endothelial
cells [21]. Simmons and colleagues probed side-speciﬁc
diﬀerences in aortic VEC gene expression [22]. Aortic side
endothelial cells showed signiﬁcantly less expression of
multiple inhibitors of cardiovascular calciﬁcation, enhanced
antioxidative gene expression, and a lack of diﬀerential
expression of proinﬂammatory molecules; suggesting that
the aortic side endothelium may be primed to protect
against inﬂammation and lesion initiation in the normal
valve. In a follow-on study, Guerraty et al. investigated
the side-speciﬁc aortic valve endothelial gene expression of
hypercholesterolemic pigs [23]. They identiﬁed diﬀerential
expression on the aortic side of caspase 3, peroxisome
proliferator-activated receptor-γ, tumor necrosis factor-α
(TNF-α), and nuclear factor-κB- (NF-κB-) related pathways
that were consistent with a protective endothelial phenotype
that persisted at 6 months. In contrast to these results,
Sucosky et al. showed that high magnitude pulsatile shear
stress applied to ﬁbrosa-side VEC (an “altered” shear stress
state) induced upregulation of inﬂammatory receptors and
expression of BMP-4 [24]. Similar to shear stress, cyclic
mechanical strain or pressure can induce and modulate
an inﬂammatory phenotype in aortic VEC [25–27]. Cyclic
tissue strain at 5% or 20% magnitude increased inﬂamma-
tory cytokine expression in aortic valve endothelium, but
decreased at 10–15% [25, 26].
VIC are a heterogeneous cell population with up to ﬁve
diﬀerent cell phenotypes (ﬁbroblasts, smooth muscle cells,
myoﬁbroblasts) in adult aortic valves [13, 15, 28–31], but
generally exhibiting ﬁbroblastic phenotypic characteristics.
Normal aortic valve interstitial cells secrete and turnover
proteins and glycosaminoglycans at a dramatically increased
rate in comparison to other cell types in vivo,w i t ha
signiﬁcantly higher index of proliferation [32]. This suggests
that VIC continually repair mechanically induced tissue
microdamage to enable long-term durability. VIC freshly
isolatedfromhigherpressureleft-sidedvalves(aortic,mitral)
were signiﬁcantly stiﬀer and had more collagen biosyn-
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pulmonary) [33]. Collagen synthesis by valve interstitial cells
was shown to be dependent upon the degree and duration
of stretch by Ku et al., as there was a signiﬁcant increase
in [3H]-proline incorporation into stretched valve cells at
10%, 14%, and 20% stretch [34]. These results indicate that
VIC-mediated matrix remodeling is regulated in part by the
magnitude of local mechanical signaling. VIC exposed to
15% “pathological” cyclic strain increased expression of α-
smooth muscle actin (α-SMA), bone morphogenic protein
(BMP)-2/4, matrix metalloproteases (MMP) and cathepsin
activity, apoptosis, and osteoblastic protein expression, but
not at 10% [27]. Hypertensive (170mmHg) cyclic pressure
also increased expression of VCAM-1 and downregulated
osteopontin [35]. VIC-VEC cocultures within 3D type I
collagen scaﬀolds suggest that VEC help maintain a quies-
cent VIC ﬁbroblastic phenotype [36, 37]. The presence of
endothelial cells stabilized VIC proliferation, promoted a
quiescent VIC phenotype, increased VIC protein synthesis,
and decreased glycosaminoglycan loss [37]. The addition of
steady shear stress to the cocultures further enhanced the
eﬀects of the endothelial cells, including a further decrease
in myoﬁbroblastic markers and increase in protein synthesis
[37].
4. Inﬂammation and CalciﬁcAortic
Valve Disease
The cause of calciﬁc aortic valve disease (CAVD) is not
completely deﬁned, but inﬂammation plays a lead role
in the initiation and progression of CAVD. Adhesion
molecules, such as ICAM-1, VCAM-1, PECAM-1, CD34,
and E-selectin, promote the participation of endothelial cells
(EC) in both physiological and pathological inﬂammatory
responses through the recruitment of leukocytes [38]. EC
become activated, which is a phenotypic change character-
ized by the production of a variety of biologically active
products (cytokines, growth factors, proteolytic enzymes,
adhesion molecules), an increase in adhesion molecule
expression, endothelial-leukocyte interaction, and perme-
ability, in response to stimuli including circulating inﬂam-
matory cytokines, lipopolysaccharides, activation of the
renin-angiotensin system, hypercholesteremia, CD40/CD40
ligand interactions, ischemia-reperfusion, physical trauma,
diabetes, and hemodynamic forces [38–41]. In diseased
aortic valves, VEC upregulate ICAM-1, VCAM-1, and E-
selectin, and this occurs preferentially on the ﬁbrosa surface
ofthevalve[24,38,40].Theﬁbrosaoraorticsideofthevalve
is also exposed to disturbed, oscillatory ﬂow, high bending
stresses, and is where calciﬁc degeneration initiates [19, 42–
45]. The hemodynamics on the valve ﬁbrosa may make
the cells more susceptible to inﬂammatory cell inﬁltration.
In vitro, disturbed ﬂow has been shown to cause pro-
inﬂammatory cytokine release (BMP-2/4) and a pro-oxidant
phenotype (NADPH, ROS) in VEC [21, 24, 46]. Oxidative,
inﬂammatory,and chondrogenic/osteogenic geneexpression
proﬁles are upregulated in vitro in VEC grown under
static conditions, which mimic hemodynamic conditions on
the ﬁbrosa side, when compared with steady shear stress
conditions, which recreate ventricularis side hemodynamics
[21, 47]. Evidence of leaﬂet stress promoting CAVD is the
discrepancy in age at the time of presentation with tricuspid
and bicuspid valves [48]. Patients with bicuspid valves,
whicharesubjectedtohighermechanicalstresses,onaverage
present with CAVD two decades younger than those with
tricuspid valves [49, 50].
Atherosclerotic risk factors, such as increased low-
density lipoprotein cholesterol, increased lipoprotein(a),
male gender, cigarette smoking, hypertension, elevated body
mass index, and diabetes, increase the incidence of aortic
stenosis and likely contribute to valve endothelial dysfunc-
tion [44, 51, 52]. The dysfunctional, activated VEC in
early valve disease have increased permeability and upreg-
ulated adhesion molecule expression. Monocytes attach to
adhesion molecules, migrate into the subendothelial space
of the valve, and diﬀerentiate into macrophages [38, 40,
53]. Macrophages and T-lymphocytes have been shown to
be present in aortic valve lesions [54–56]. These invad-
ing inﬂammatory cells, and likely the resident activated
endothelial cells, secrete a number of cytokines and/or
chronic inﬂammation eﬀector molecules (e.g., HLA-DR
IL-1β/2/6, TNF-α,T G F β-1, BMP-2/4/7) [43, 56–59]. In
addition, circulating low density lipoproteins (LDL) are
able to migrate through the permeable endothelial layer,
and oxidized forms are capable of deep tissue penetration
[60, 61]. Sub-endothelial LDL accumulation can recruit
additional inﬂammatory cells by mechanisms including
the induction of macrophage chemoattractants, adhesion
molecules, and cytokines [62, 63]. Circulating LDL particles
may also deliver angiotensin converting enzyme (ACE) to
valve lesions [64]. Angiotensin II, which is generated from
angiotensin I by ACE, can compound the inﬂammatory
responses already present by stimulating inﬂammation and
macrophage cholesterol accumulation, increasing oxidant
stress, and impairing ﬁbrinolysis [65].
The cytokines and inﬂammatory eﬀector molecules
secreted into the subendothelium and ﬁbrosa by immune
cells and activated endothelial cells contribute to a local
biochemical environment that promotes VIC diﬀerentiation,
matrix remodeling, neovascularization, ﬁbrosis, and calciﬁ-
cation. TGFβ-1, BMP-2/4/7, IL-1β,T N F - α,l i p o p o l y s a c c h a -
ride, and peptidoglycan have been shown to induce myoﬁ-
broblasticdiﬀerentiation,theexpressionofproinﬂammatory
mediators, or the upregulation of osteogenesis-associated
factors in VIC when applied individually in vitro [43, 57, 59,
66–69]. Impaired anti-inﬂammation mechanisms may also
contribute to VIC-mediated pathogenesis of aortic stenosis
as interleukin-1 receptor antagonist, which is the antagonist
of interleukin-1β, was shown to be abundant in nonstenotic
aortic valve leaﬂets and nearly absent in leaﬂets from stenotic
valves [70]. Myoﬁbroblastic activation is characterized by an
increase in myoﬁbroblast markers such as vimentin, α-SMA,
and embryonic nonmuscle myosin heavy chain (SMemb);
and increased cell migration, proliferation, and contractility
[13, 29, 31, 71–73] .A c t i v a t e dV I Ca n di n ﬂ a m m a t o r yc e l l s
secrete MMP, and cathepsins that progressively destroy the
primarily collagen and elastin valve matrix ultrastructure
[71, 74–79]. Enzymatic cleavage of ECM can release bound
growth factors such as TGFβ-1, which further promotes VIC4 International Journal of Inﬂammation
myoﬁbroblast diﬀerentiation and MMP expression [80–83].
MMP and cathepsin inhibitors, such as TIMPs and cystatin
C, are also expressed by activated VIC, but their role in
CAVD is not yet known [77, 84]. Following healthy ECM
destruction, activated VIC deposit a remodeled, ﬁbrotic
matrix characterized by disorganized collagen bundle accu-
mulation, proteoglycan degradation, and fragmentation and
stratiﬁcation of elastin ﬁbers [84–86]. This ECM remodeling
results in a stiﬀ aortic valve that is prone to restricted
movement, stenosis, and eventual calciﬁcation [85].
5. Myxomatous Degeneration of
the Mitral Valve
Myxomatous degeneration of the mitral valve or mitral valve
prolapse (MVP) is a condition diagnosed with echocar-
diographically and characterized by abnormally thickened,
redundant, ﬂoppy leaﬂets that are displaced into the left
atrium during systole [87]. MVP is estimated to aﬀect 1–
3% of the US population, and some serious complications
of the condition include progressive heart failure, throm-
boembolism, infective endocarditis, and sudden death [71,
87–90]. The mechanisms for the changes within the valve
leaﬂets are unknown, but myxomatous valvular degenera-
tion is characterized by collagen degradation, proteoglycan
accumulation, and elastin fragmentation [85, 87]. This valve
matrix remodeling allows stretching of the leaﬂets, resulting
in a ﬂoppy valve that is prone to prolapse and regurgitation.
It has been hypothesized that the leaﬂet remodeling may be a
response to repeated mechanical stress [91].
There are several connective tissue inherited disorders
that are associated with mitral valve dysfunction including
Marfan syndrome (ﬁbrillin-1 mutations), Williams syn-
drome (elastin mutations), osteogenesis imperfecta (col-
lagen 1A1 and 1A2 mutations), Ehlers-Danlos syndrome
(mutations in collagen 1A1, 3A1, 1A2, 5A1, and tenascin-
x), and Stickler syndrome (collagen 2A1 and collagen 11A1
mutations) [92–100]. MVP is generally sporadic, however,
and it is unlikely that more than 1-2% of MVP cases are
associated with a connective tissue disorder [87]. A Marfan
syndrome mouse model has indicated that increased TGF-β
signaling contributes to collagen dysregulation and loss
of valve matrix integrity in Marfan syndrome-related and
possibly other forms of MVP [101]. Fibrillin-1 interaction
with latent TGF-β binding proteins (LTBP) regulates TGF-β
activation [102, 103]. LTBP forms a bridge between matrix
microﬁbrils and latency-associated peptide (LAP), which
remains noncovalently linked to TGF-β and aids in matrix
sequestration. Work by Ng et al. suggests that TGF-β
sequestered in the TGF-β, LAP, and LTBP complex is
stabilized and/or less prone to activation due to interaction
with ﬁbrillin-1 and potentially other components of the
extracellular matrix [101]. Pharmacological inhibition of
TGF-β signaling with losartan has been shown to reduce
Marfansyndromepathologyinmiceandhumans[104,105].
Increased TGF-β signaling also supports the interstitial cell
activated myoﬁbroblast phenotype and excessive proteolytic
activity found in myxomatous valves, as TGF-β has been
shown to activate valve interstitial cells and upregulate the
expression of ECM-degrading enzymes [71, 82].
6. Rheumatic Heart Valve Disease
andInfectiveEndocarditis
Rheumatic fever (RF) is an inﬂammatory complication that
may develop after a untreated throat infection by the group
A β-hemolytic streptococcal bacteria Streptococcus pyogenes
in susceptible children and teenagers [106]. Carditis, which
is one of the most serious RF complications, occurs about
20 days after the infection in 40–50% of patients and
can lead to valvular heart disease, heart failure, or death
[107–109]. The streptococcal cell structures include the
cell wall, capsule, ﬁmbriae, peptidoglycans, cytoplasmic
membrane, group-speciﬁc carbohydrates, and the M, T, and
R antigenic proteins [110]. The streptococcal M protein and
hyaluronic acid capsule have been established as the most
important virulence factors in human infections, as both
confer antiphagocytic properties upon the streptococcal cell
and patients with acute RF have a high level of antibodies
to streptococcal M protein [111–115]. The M protein is
attached to the bacterial cell wall and membrane and extends
from the cell surface as an alpha-helical coiled-coil dimer
[116, 117].
RF-related cardiac complications are the result of an
autoimmune reaction induced by molecular mimicry of
human tissues by streptococcal M proteins [108]. The
alpha-helical coiled-coil dimer streptococcal M protein has
been shown to be structurally and immunologically similar
to cardiac myosin, a known mediator of inﬂammatory
heart disease, and other alpha-helical coiled-coil molecules
[118]. The antistreptococcal/antimyosin monoclonal anti-
body mAb 3B6 from rheumatic carditis has shown that
the group A streptococcal M protein N-acetylglucosamine,
which is the dominant group A carbohydrate epitope, and
cardiac myosin in the myocardium are the cross-reactive
antigens involved in antibody deposition on the valve [119].
Cardiac myosin is not part of the valve, but mAB 3B6 was
also shown to recognize laminin, a valvular extracellular
matrix protein with alpha-helical coiled-coil domains that
are highly homologous with streptococcal M proteins and
cardiac myosins [118, 119].
In acute rheumatic carditis host M-protein antibodies
bind the valve surface endothelium and/or the valve base-
ment membrane structure protein laminin, which upregu-
lates the endothelial expression of inﬂammatory adhesion
molecules such as VCAM-1 [120]. The inﬂamed valvular
endothelium leads to T-cell recruitment and inﬁltration
through the endothelial layer [118]. T-lymphocytes enter the
valve interstitium and cause further inﬂammation, degen-
eration, and remodeling. The resulting valve pathologies
include neovascularization, chronic inﬂammation, commis-
sural fusion, thickening, calciﬁcation, and thickened and
shortened chordae in the atrioventricular valves [108].
Infective endocarditis (IE) is inﬂammation of the endo-
cardial surfaces of the heart, most commonly the heart
valve, caused by the presence of bacteria in the bloodstream
and bacterial vegetations forming on valve leaﬂets [121].International Journal of Inﬂammation 5
The bacterial strains that cause IE include staphylococci,
streptococci, and enterococcus, and the complications from
this type of infection include severe valvular dysfunction,
congestive heart failure, and death [122]. If there is altered
blood ﬂow around the valves or the valves have been
damaged, from mitral valve regurgitation and thickening
due to rheumatic fever, for example, the risk of bacterial
attachment increases [121].
The bacterial vegetations that form on the valve sur-
face are composed of platelets, ﬁbrin, microorganisms,
and inﬂammatory cells and are the result of mechani-
cal or inﬂammatory valve lesions [121, 123]. Mechani-
cally denuded endothelial layer lesions promote microbial
adherence to the endothelium when bacteria is present
in the bloodstream [123]. Endothelial denudation results
in direct contact between blood and proteins within the
valve interstitium, which include extracellular matrix pro-
teins, thromboplastin, and tissue factor, and causes blood
coagulation [123]. The damaged endothelium is colonized
when microorganisms bind to the ﬁbrin and platelet-
containing blood clots and initiate monocyte activation and
production of cytokines and tissue factor activity (TFA)
[124].ThevegetationgrowswhencytokinesandTFAactivate
coagulation cascades, attract and activate blood platelets,
and induce cytokine, integrin, and TFA production from
nearby endothelial cells [123]. Inﬂammatory lesions are the
result of endothelial cells responding to local inﬂammation
by expressing β1 integrins, including very late antigen (VLA)
[125]. β1 integrins bind ﬁbronectin to the valve endothelial
surface [123]. IE-associated pathogens have ﬁbronectin-
binding proteins on their surface, therefore β1 integrins
provide an adhesive surface for the circulating microor-
ganisms [123]. Following pathogen adhesion, endothelial
cells internalize the bacteria; which causes endothelial TFA
and cytokines production, blood clotting, the extension
of inﬂammation, and vegetation growth [123, 126]. Inter-
nalised bacteria eventually lyse endothelial cells by secreting
membrane active proteins such as hemolysins [123]. The
vegetation growth and tissue damage caused by mechanical
or inﬂammatory lesions can result in abscess formation and
septic emboli may circulate to other organs [127].
7.SerotoninMetabolism-Related
Valve Disorders
Clinical studies have identiﬁed an increased incidence of
ﬁbrotic aortic valve disease in patients using several classes
of drugs that are structurally similar to serotonin (5-
hydroxytryptamine, 5-HT) and in patients with carcinoid
syndrome, which can result in a high serotonin concen-
tration on the right side of the heart [128–131]. External
serotonin administration in vitro and in vivo has been shown
to increase VIC proliferation and α-SMA, collagen, and
TGFβ expression, which are all indicative of myoﬁbroblastic
activation and ﬁbrotic matrix remodeling [132–135]. No
studies have directly linked aortic valve calciﬁcation and
elevated serotonin levels; however, serotonin may mediate
intermediate stage valve ﬁbrosis. Recent evidence supports
serotonin synthesis by valve cells [136]. This may contribute
to valve calciﬁcation through increased TGFβ signaling by
serotonin receptor antagonists or transporter agonists in
mitral valves [136]. The eﬀects of serotonin on VEC are
less well understood, but endothelial function is required for
serotonin-mediatedvalverelaxation[137,138].Theseresults
suggestthatcontrollingserotoninmetabolismmaybeanovel
means of selectively modulating valve cell phenotype in vivo.
8. BoneMarrowStemCellContributiontoValve
RepairandDisease
Bone marrow-derived mesenchymal stem cells (BMSCs) are
f o u n di na d u l tc i r c u l a t i o na tal o wc o n c e n t r a t i o na n da r e
thought to regulate the immune response in settings such
as tissue injury, transplantation, and autoimmunity [139].
Mouse and human valve studies have shown that at least
10% of VIC are BMSCs, but the speciﬁc role of BMSCs
in valve disease is not well understood [140, 141]. The
progenitors appear to be recruited with other inﬂammatory
cells into the valve interstitium, but whether they initiate
repair or promote disease is unclear. Tanaka et al. identiﬁed
bone marrow-derived cells expressing myoﬁbroblast and
osteoblast markers near calciﬁc nodules in aged mice,
which was supported in humans by Helske et al. [79].
Understanding the recruitment and function of circulating
stem cells in valve homeostasis and pathogenesis could have
clinical beneﬁts, as autologous BMSCs may be treated to
express antiﬁbrotic and anticalciﬁc proteins before their
mobilization to valves [142].
9. Inﬂammation andValve Tissue Engineering
Tissue engineered heart valves could provide a great clinical
beneﬁt to patients with valve disease, especially children
who require valve growth and younger patients who cannot
tolerate the side eﬀects of nonliving prosthetics [143, 144].
Understanding the role of host inﬂammatory response is
essential to the successful implantation of tissue engineered
valves, however. Repopulation and regeneration are the two
main heart valve tissue engineering approaches that have
been attempted [145]. A repopulated heart valve is created
when a patient’s cells repopulate an implanted decellularized
porcine aortic valve [145]. A heart valve is regenerated by
implantation of a resorbable matrix that remodels in vivo,
resulting in a functional valve composed of the patient’s
cells and connective tissue proteins [145]. Neither of these
approaches have achieved clinical success, however.
Long-term sheep implantation studies with decellular-
ized heart valves and acellular valves seeded with cells
before implantation showed signiﬁcant tissue overgrowth,
inﬁltration with inﬂammatory cells, and dilatation [146,
147]. The SynerGraft valve by CryoLife is a decellularized
pulmonary valve that has been implanted in humans.
Adult clinical trials have been encouraging, but in children,
rapid inﬂammatory reactions caused death in 3 out of 4
patients [148, 149]. All pediatric valves displayed severe
inﬂammation,includingﬁbrosis,encapsulation,perforation,
and deterioration of the leaﬂet tissues [149]. Matrix P
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valves, displayed early obstruction following implantation
in pediatric patients [150]. A foreign body-type reaction
accompanied by severe ﬁbrosis and massive neointima
formation around the decellularized porcine valve wall
was found. Examination of the explanted valves showed
inﬂammatory inﬁltrates, composed of T cells, B cells, plasma
cells, dendritic cells, macrophages, and mast cells, in the
tissue surrounding the porcine matrix. In vitro studies have
shown that the inﬂammatory mechanism of decellularized
valves may involve porcine collagen type I, but not porcine
elastin [151].
In one of the few long-term in vivo studies with poly-
meric tissue engineered heart valves, composite biodegrad-
able polymer valves were seeded with mesenchymal stem
cells, cultured for 4 weeks, and implanted into a sheep
model for up to 20 weeks [152]. In vivo monitoring showed
leaﬂet coaptation, and explanted valves showed near-native
trilaminar matrix striation with both endothelial-like and
interstitial-like cell phenotypes. Elevated transvalvular pres-
sure gradients, however, suggest that the cusps are still too
stiﬀ. Interestingly, these valves exhibited a marked inﬂam-
matory activation during their early remodeling period,
characterized by the presence of endothelial inﬂammatory
receptors (VCAM-1, ICAM-1), matrix metalloproteases,
and interstitial cell myoﬁbroblastic activation. Early matrix
structurewasvirtuallyabsentanddisorganized.After2-week
in vitro conditioning, and further enhanced with in vivo
implantation, the progression to organized tissue striation
correlated inversely with the degree of activated valve cell
phenotypes. Collectively, these results demonstrate that the
degree of inﬂammation has a signiﬁcant role on the fate of
engineered tissues, and suggests that progressively reduced
inﬂammation can help develop and maintain quiescent
tissue.
10. Inﬂammatory Regulation of
Valve Formation
The morphogenesis of the atrioventricular and semilunar
valves is a complex process that occurs along with the
changing cardiac morphology and hemodynamics of the
growing embryo. The early embryonic heart is a tube of
endocardium surrounded by myocardium [153]. Soon after
the linear heart tube begins to loop the myocardium secretes
cardiac jelly, a hyaluronan and chondroitin sulfate rich
gelatinous matrix, into the atrioventricular (AV) junction
and outﬂow tract (OFT) lumen [154–157]. At chick stage
HH14 (mouse E9.0, human day 20), valvulogenesis begins
when a subset of endocardial cells receive growth factor
signals from the myocardium that initiate a cascade of
signal pathways resulting in an endocardial to mesenchymal
transformation (EMT) [153, 158]. EMT is characterized by
endocardial cell activation; three antigens expressed only by
activated endocardial cells include ES130, JB3/ﬁbrillin, and
TGFβ3[ 159–161]. Activated endocardial cells lose cell-cell
contacts proteins (PECAM1, NCAM1, DS-CAM), gain cell-
matrix adhesions (integrins), gain mesenchymal markers (α-
smoothmuscleactin,α-SMA),andtheacquirecellmigratory
and invasive capacity (transformation) [153, 157, 158, 162,
163]. The transformed endocardial cells invade the cardiac
jelly and form the endocardial cushions that will eventually
develop into mature atrioventricular and semilunar valves
[157, 162].
Fewstudieshavebeenperformedtodeterminetheroleof
inﬂammation on valve development. A recent study showed
that leptin, a member of the IL-6 superfamily, mediates
embryonic EMT [164]. TNF-α serum levels were found
to be high in children with congenital heart disease and
TNF-α and IL-6 levels were elevated in the myocardium
of infants with tetralogy of Fallot or ventricular septal
defects [165, 166]. Neonates with hypoplastic left-heart
syndrome (HLHS) have evidence of an activated inﬂamma-
tory response, as IL-6 levels are signiﬁcantly elevated when
compared with controls [167]. Fetal aortic valve endothelial
cells express ICAM-1 and VCAM-1, but whether this is due
to inﬂammation is unknown [41]. VCAM-1 deﬁcient mice
survive to E11.5–12.5 and display severe heart abnormalities
including a reduction of the compact layer of the ventricular
myocardium and intraventricular septum, blood in the
pericardial space, and an absent epicardium [168].
Abnormal inﬂammatory signaling may play a role in the
development of congenital heart defects. Children born to
mothers’ with the connective tissue disease lupus erythe-
matosus (LE) have an increased risk for congenital heart
block (CHB), a type of arrhythmia, and valve regurgitation
[169, 170]. CHB can result in early death from delayed
pacemaker placement or hemodynamic compromise from
associated congenital heart disease [171]. The fetal heart
defects resulting from maternal LE are thought to be the
result of transplacental passage of certain maternal autoan-
tibodies, including immunoglobulin G (IgG) antibodies to
SSA/Ro and SSB/La ribonucleoproteins [169, 172]. These
autoantibodies damage the fetal AV conduction tissue by
inﬂammation in the early stage and later by ﬁbrosis [173].
Maternal inﬂammatory insult has also been shown to result
in fetal cardiac dysfunction [174]. Administration of intra-
amniotic lipopolysaccharide caused an increase in maternal
TNF-α and IL-6 serum levels, and the placenta showed
severe maternal vascular dilatation and congestion [175].
No inﬂammatory activation was found in the fetal tissues,
and the amniotic ﬂuid revealed no signiﬁcant increase in
cytokines; but ultrasonographic examination of the fetal
hearts showed that 65% of the fetuses exhibited atrioven-
tricular valve regurgitation [175]. The maternal inﬂamma-
tory insult was shown to activate placental labyrinthine
macrophages, which then leads to an acute increase in
placental vascular resistance and fetal cardiac dysfunction
[175].
A b n o r m a ln u c l e a rf a c t o r - K a p p aB( N F - κB) activation
may play a role in congenital heart defects. NF-κBi s
a transcription factor that coordinates inﬂammation and
cellular proliferation. Upregulated NF-κB activation was
found in the myocardium of children with congenital heart
disease and in the myocardium of infants with tetralogy
of Fallot or ventricular septal defects [165, 166]. The
inhibitionofNF-κBduringchickenheartdevelopmentledto
impaired OFT development and resulted in interventricular
communication, double outlet right ventricle, and valvularInternational Journal of Inﬂammation 7
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Figure 1: Inﬂammation and its signaling partners are involved
in every stage of the heart valve life cycle, from embryonic
morphogenesis (top), quiescent adult valve homeostasis (middle),
and in valve pathology (bottom). Many structural and biological
features of diseased valves resemble those from embryonic/fetal
valves, suggesting similar signaling pathways are reactivated. Iden-
tifying and controlling these pathways represents an important
and challenging task with potential for large payoﬀ for heart valve
disease diagnosis and treatment.
and great arteries stenosis [176]. Nuclear factor of activated
Tcells(NF-ATc)isatranscriptionfactorsthatmaybeneeded
for cytokine gene expression in activated lymphocytes. Mice
lacking NF-ATc died in utero from congestive heart failure
at days 13.5–17.5 of gestation due to the absence pulmonary
and aortic valve leaﬂets [177]. Adults with congenital heart
disease were found to have elevated levels of endotoxin
and of the inﬂammatory cytokines TNF-α and IL-6 when
compared to controls, which indicates that adults with
congenital heart disease could potentially beneﬁt from novel
anti-inﬂammatory therapies [178].
11. Conclusions
These studies highlight our evolving understanding of the
complex role of inﬂammation in heart valve remodeling,
and underscore how much more is left to be learned.
While it is true that inﬂammation mediates the ugliest of
pathological valve remodeling, the fact that it is also present
during normal embryonic development suggests a potential
beneﬁt. Indeed, inﬂammation-mediated tissue formation,
for example, during foreign body encapsulation, is among
the most rapid processes available in our natural arsenal.
Embryonic morphogenesis progresses on a signiﬁcantly
more rapid scale than wound healing, yet instead of ﬁbrosis
results in scar-free, mature tissue architectures. It is therefore
time to reconsider the myopic view of inﬂammation as the
harbinger of destruction, but rather as a universal agent
of tissue remodeling, for good or ill. In this light, many
more questions are revealed rather than answered (Figure 1).
How does inﬂammation promote positive remodeling, and
what are the triggers for pathological change? Are there
signaling paradigms in embryonic valve formation that are
reactivated in pathological valve remodeling? If so, how
are these controlled by inﬂammation? The answers will
likely be heavily dependent on the microenvironmental
context (patient age, gender, underlying inﬂammatory state,
gene mutations, mechanical stress, etc.). However, this
transformative notion suggests a new avenue to promote
and control tissue remodeling in adaptive and regenerative
heart valve applications. It is not yet known whether or how
this may be achieved in tissue engineering applications, but
strongly suggests that complete cessation of inﬂammatory
signaling may not be the best approach. We hope with future
research in this area these answers will lead to new clinically
translatable therapies for patients with valve disease.
Acknowledgments
ThispaperwassupportedbygrantsfromtheAmericanHeart
Association(J.T.Butcher),TheNationalScienceFoundation
(J. T. Butcher), and The Hartwell Foundation (J. T. Butcher
and G. J. Mahler). The authors have no ﬁnancial conﬂicts of
interests to disclose.
References
[1] A. J. Singer and R. A. F. Clark, “Cutaneous wound healing,”
The New England Journal of Medicine, vol. 341, no. 10, pp.
738–746, 1999.
[2] X. J. Wang, G. Han, P. Owens, Y. Siddiqui, and A. G. Li,
“Role of TGFβ-mediated inﬂammation in cutaneous wound
healing,” Journal of Investigative Dermatology Symposium
Proceedings, vol. 11, no. 1, pp. 112–117, 2006.
[3] R. F. Diegelmann and M. C. Evans, “Wound healing: an
overview of acute, ﬁbrotic and delayed healing,” Frontiers in
Bioscience, vol. 9, pp. 283–289, 2004.
[4] S. O’Kane and M. W. J. Ferguson, “Transforming growth
factor βs and wound healing,” International Journal of
Biochemistry & Cell Biology, vol. 29, no. 1, pp. 63–78, 1997.
[5] J. Massague, “The transforming growth factor-β family,”
Annual Review of Cell Biology, vol. 6, pp. 597–641, 1990.
[6] M.J .Cro we,T .Doetschman,andD .G.Greenhalgh,“Dela yed
wound healing in immunodeﬁcient TGF-β1 knockout mice,”
Journal of Investigative Dermatology, vol. 115, no. 1, pp. 3–11,
2000.
[ 7 ]A .B .R o b e r t s ,M .B .S p o r n ,R .K .A s s o i a ne ta l . ,“ T r a n s -
forming growth factor type β: rapid induction of ﬁbrosis and
angiogenesisinvivoandstimulationofcollagenformationin
vitro,” Proceedings of the National Academy of Sciences of the
UnitedStatesofAmerica,vol.83,no.12,pp.4167–4171,1986.
[8] L. S. Beck, L. Deguzman, W. P. Lee, Y. Xu, L. A. McFatridge,
and E. P. Amento, “TGF-β1 accelerates wound healing:
reversal of steroid-impaired healing in rats and rabbits,”
Growth Factors, vol. 5, no. 4, pp. 295–304, 1991.
[9] M. Shah, D. M. Foreman, and M. W. J. Ferguson, “Neutralis-
ingantibodytoTGF-β1,2reducescutaneousscarringinadult
rodents,” Journal of Cell Science, vol. 107, no. 5, pp. 1137–
1157, 1994.
[ 1 0 ]X .W a n g ,P .S m i t h ,L .L .Q .P u ,Y .J .K i m ,F .K o ,a n dM .C .
Robson, “Exogenous transforming growth factor β2m o d u -
lates collagen I and collagen III synthesis in proliferative scar8 International Journal of Inﬂammation
xenografts in nude rats,” The Journal of Surgical Research, vol.
87, no. 2, pp. 194–200, 1999.
[ 1 1 ]M .S h a h ,D .M .F o r e m a n ,a n dM .W .J .F e r g u s o n ,“ N e u t r a l i -
sationofTGF-β1andT GF -β2orexogenousadditionofTGF-
β3 to cutaneous rat wounds reduces scarring,” Journal of Cell
Science, vol. 108, no. 3, pp. 985–1002, 1995.
[12] G. W. Christie, “Anatomy of aortic heart valve leaﬂets: the
inﬂuence of glutaraldehyde ﬁxation on function,” European
Journal of Cardio-Thoracic Surgery, vol. 6, no. 1, pp. S25–S33,
1992.
[13] P. M. Taylor, P. Batten, N. J. Brand, P. S. Thomas, and M.
H. Yacoub, “The cardiac valve interstitial cell,” International
Journal of Biochemistry & Cell Biology, vol. 35, no. 2, pp. 113–
118, 2003.
[14] E. Poggianti, L. Venneri, V. Chubuchny, Z. Jambrik, L.
A. Baroncini, and E. Picano, “Aortic valve sclerosis is
associated with systemic endothelial dysfunction,” Journal of
the American College of Cardiology, vol. 41, no. 1, pp. 136–
141, 2003.
[15] D. L. Mulholland and A. I. Gotlieb, “Cell biology of valvular
interstitial cells,” Canadian Journal of Cardiology, vol. 12, no.
3, pp. 231–236, 1996.
[16] J. T. Butcher, C. A. Simmons, and J. N. Warnock,
“Mechanobiology of the aortic heart valve,” The Journal of
Heart Valve Disease, vol. 17, no. 1, pp. 62–73, 2008.
[17] K. J. Grande-Allen and J. Liao, “The heterogeneous biome-
chanicsandmechanobiologyofthemitralvalve:implications
for tissue engineering,” Current Cardiology Reports, vol. 13,
no. 2, pp. 113–120, 2011.
[18] M. W. Weston, D. V. LaBorde, and A. P. Yoganathan,
“Estimation of the shear stress on the surface of an aortic
valve leaﬂet,” Annals of Biomedical Engineering, vol. 27, no.
4, pp. 572–579, 1999.
[ 1 9 ] P .J .K i l n e r ,G .Z .Y a n g ,A .J .W i l k e s t ,R .H .M o h l a d d l i n ,D .N .
Firmin, and M. H. Yacoub, “Asymmetric redirection of ﬂow
through the heart,” Nature, vol. 404, no. 6779, pp. 759–761,
2000.
[20] J. T. Butcher, A. M. Penrod, A. J. Garc´ ıa, and R. M. Nerem,
“Unique morphology and focal adhesion development of
valvular endothelial cells in static and ﬂuid ﬂow environ-
ments,” Arteriosclerosis, Thrombosis, and Vascular Biology,
vol. 24, no. 8, pp. 1429–1434, 2004.
[21] J. T. Butcher, S. Tressel, T. Johnson et al., “Transcriptional
proﬁles of valvular and vascular endothelial cells reveal phe-
notypic diﬀerences: inﬂuence of shear stress,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 26, no. 1, pp. 69–77,
2006.
[ 2 2 ]C .A .S i m m o n s ,G .R .G r a n t ,E .M a n d u c h i ,a n dP .F .D a v i e s ,
“Spatial heterogeneity of endothelial phenotypes correlates
with side-speciﬁc vulnerability to calciﬁcation in normal
porcine aortic valves,” Circulation Research, vol. 96, no. 7, pp.
792–799, 2005.
[23] M. A. Guerraty, G. R. Grant, J. W. Karanian, O. A. Chiesa,
W. F. Pritchard, and P. F. Davies, “Hypercholesterolemia
induces side-speciﬁc phenotypic changes and peroxisome
proliferator-activated receptor-γ pathway activation in swine
aortic valve endothelium,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 30, no. 2, pp. 225–231, 2010.
[ 2 4 ]P .S u c o s k y ,K .B a l a c h a n d r a n ,A .E l h a m m a l i ,H .J o ,a n dA .P .
Yoganathan, “Altered shear stress stimulates upregulation of
endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGF-
β1-dependent pathway,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 29, no. 2, pp. 254–260, 2009.
[25] S. A. Metzler, C. A. Pregonero, J. T. Butcher, S. C. Burgess,
andJ.N.Warnock,“Cyclicstrainregulatespro-inﬂammatory
protein expression in porcine aortic valve endothelial cells,”
The Journal of Heart Valve Disease, vol. 17, no. 5, pp. 571–
578, 2008.
[26] K. E. Smith, S. A. Metzler, and J. N. Warnock, “Cyclic
strain inhibits acute pro-inﬂammatory gene expression in
aortic valve interstitial cells,” Biomechanics and Modeling in
Mechanobiology, vol. 9, no. 1, pp. 117–125, 2010.
[27] K. Balachandran, P. Sucosky, H. Jo, and A. P. Yoganathan,
“Elevated cyclic stretch induces aortic valve calciﬁcation in
a bone morphogenic protein-dependent manner,” American
Journal of Pathology, vol. 177, no. 1, pp. 49–57, 2010.
[28] J. Yperman, G. De Visscher, P. Holvoet, and W. Flameng,
“Molecular and functional characterization of ovine cardiac
valve-derived interstitial cells in primary isolates and cul-
tures,” Tissue Engineering, vol. 10, no. 9-10, pp. 1368–1375,
2004.
[29] A. C. Liu, V. R. Joag, and A. I. Gotlieb, “The emerging role
of valve interstitial cell phenotypes in regulating heart valve
pathobiology,” American Journal of Pathology, vol. 171, no. 5,
pp. 1407–1418, 2007.
[30] R.H.Messier,B.L.Bass,H.M.Alyetal.,“Dualstructuraland
functional phenotypes of the porcine aortic valve interstitial
population: characteristics of the leaﬂet myoﬁbroblast,” The
Journal of Surgical Research, vol. 57, no. 1, pp. 1–21, 1994.
[31] E. Rabkin-Aikawa, M. Farber, M. Aikawa, and F. J. Schoen,
“Dynamic and reversible changes of interstitial cell pheno-
type during remodeling of cardiac valves,” The Journal of
Heart Valve Disease, vol. 13, no. 5, pp. 841–847, 2004.
[32] P. J. Schneider and J. D. Deck, “Tissue and cell renewal in
the natural aortic valve of rats: an autoradiographic study,”
Cardiovascular Research, vol. 15, no. 4, pp. 181–189, 1981.
[33] W. D. Merryman, I. Youn, H. D. Lukoﬀ et al., “Correlation
between heart valve interstitial cell stiﬀness and transvalvular
pressure: implications for collagen biosynthesis,” American
Journal of Physiology, vol. 290, no. 1, pp. H224–H231, 2006.
[34] C. H. Ku, P. H. Johnson, P. Batten et al., “Collagen synthesis
by mesenchymal stem cells and aortic valve interstitial cells
in response to mechanical stretch,” Cardiovascular Research,
vol. 71, no. 3, pp. 548–556, 2006.
[35] J. N. Warnock, S. C. Burgess, A. Shack, and A. P. Yoganathan,
“Diﬀerential immediate-early gene responses to elevated
pressure in porcine aortic valve interstitial cells,” Journal of
Heart Valve Disease, vol. 15, no. 1, pp. 34–42, 2006.
[36] M. Rothenburger, W. V¨ olker, P. Vischer et al., “Tissue
engineeringofheartvalves:formationofathree-dimensional
tissue usingporcine heart valve cells,” ASAIOJournal, vol. 48,
no. 6, pp. 586–591, 2002.
[37] J. T. Butcher and R. M. Nerem, “Valvular endothelial cells
regulate the phenotype of interstitial cells in co-culture:
eﬀects of steady shear stress,” Tissue Engineering, vol. 12, no.
4, pp. 905–915, 2006.
[38] A. M. M¨ u l l e r ,C .C r o n e n ,L .I .K u p f e r w a s s e r ,H .O e l e r t ,K .
M. M¨ uller, and C. J. Kirkpatrick, “Expression of endothelial
cell adhesion molecules on heart valves: up-regulation in
degeneration as well as acute endocarditis,” The Journal of
Pathology, vol. 191, no. 1, pp. 54–60, 2000.
[39] S. P. Alom-Ruiz, N. Anilkumar, and A. M. Shah, “Reactive
oxygen species and endothelial activation,” Antioxidants and
Redox Signaling, vol. 10, no. 6, pp. 1089–1100, 2008.
[40] N.K.Ghaisas,J.B.Foley,D.S.O’Briain,P.Crean,D.Kelleher,
and M. Walsh, “Adhesion molecules in nonrheumatic aortic
valve disease: endothelial expression, serum levels and eﬀectsInternational Journal of Inﬂammation 9
of valve replacement,” Journal of the American College of
Cardiology, vol. 36, no. 7, pp. 2257–2262, 2000.
[41] E. Aikawa, P. Whittaker, M. Farber et al., “Human semilunar
cardiac valve remodeling by activated cells from fetus to
adult: implications for postnatal adaptation, pathology, and
tissue engineering,” Circulation, vol. 113, no. 10, pp. 1344–
1352, 2006.
[42] E. R. Mohler, “Are atherosclerotic processes involved in
aortic-valve calciﬁcation?” The Lancet, vol. 356, no. 9229, pp.
524–525, 2000.
[43] E. R. Mohler, F. Gannon, C. Reynolds, R. Zimmerman, M. G.
Keane, and F. S. Kaplan, “Bone formation and inﬂammation
in cardiac valves,” Circulation, vol. 103, no. 11, pp. 1522–
1528, 2001.
[44] E. R. Mohler, “Mechanisms of aortic valve calciﬁcation,” The
American Journal of Cardiology, vol. 94, no. 11, pp. 1396–
1402, 2004.
[45] M. J. Thubrikar, J. Aouad, and S. P. Nolan, “Patterns of
calciﬁc deposits in operatively excised stenotic or purely
regurgitant aortic valves and their relation to mechanical
stress,” The American Journal of Cardiology,v o l .5 8 ,n o .3 ,p p .
304–308, 1986.
[46] G.P.Sorescu,H.Song,S.L.Tresseletal.,“Bonemorphogenic
protein 4 produced in endothelial cells by oscillatory shear
stress induces monocyte adhesion by stimulating reactive
oxygen species production from a Nox1-based NADPH
oxidase,” Circulation Research, vol. 95, no. 8, pp. 773–779,
2004.
[47] C. Y. Y. Yip and C. A. Simmons, “The aortic valve microen-
vironment and its role in calciﬁc aortic valve disease,”
Cardiovascular Pathology, vol. 20, no. 3, pp. 177–182, 2011.
[48] R. V. Freeman and C. M. Otto, “Spectrum of calciﬁc
aortic valve disease: pathogenesis, disease progression, and
treatment strategies,” Circulation, vol. 111, no. 24, pp. 3316–
3326, 2005.
[49] S. Beppu, S. Suzuki, H. Matsuda, F. Ohmori, S. Nagata,
and K. Miyatake, “Rapidity of progression of aortic stenosis
in patients with congenital bicuspid aortic valves,” The
American Journal of Cardiology, vol. 71, no. 4, pp. 322–327,
1993.
[50] R. T. Pachulski and K. L. Chan, “Progression of aortic
valve dysfunction in 51 adult patients with congenital
bicuspid aortic valve: assessment and follow up by Doppler
echocardiography,” British Heart Journal,v o l .6 9 ,n o .3 ,p p .
237–240, 1993.
[51] B. F. Stewart, D. Siscovick, B. K. Lind et al., “Clinical factors
associated with calciﬁc aortic valve disease,” Journal of the
American College of Cardiology, vol. 29, no. 3, pp. 630–634,
1997.
[52] W. S. Aronow, C. Ahn, I. Kronzon, and M. E. Goldman,
“Association of coronary risk factors and use of statins with
progression of mild valvular aortic stenosis in older persons,”
The American Journal of Cardiology, vol. 88, no. 6, pp. 693–
695, 2001.
[53] C. N. Shahi, N. K. Ghaisas, M. Goggins et al., “Elevated
levels of circulating soluble adhesion molecules in patients
with nonrheumatic aortic stenosis,” The American Journal of
Cardiology, vol. 79, no. 7, pp. 980–982, 1997.
[54] M. Olsson, C. J. Dalsgaard, A. Haegerstrand, M. Rosenqvist,
L. Ryden, and J. Nilsson, “Accumulation of T lymphocytes
and expression of interleukin-2 receptors in nonrheumatic
stenotic aortic valves,” Journal of the American College of
Cardiology, vol. 23, no. 5, pp. 1162–1170, 1994.
[ 5 5 ]C .M .O t t o ,J .K u u s i s t o ,D .D .R e i c h e n b a c h ,A .M .G o w n ,
and K. D. O’Brien, “Characterization of the early lesion
of ’degenerative’ valvular aortic stenosis: histological and
immunohistochemicalstudies,”Circulation,vol.90,no .2,pp .
844–853, 1994.
[56] M. Olsson, M. Rosenqvist, and J. Nilsson, “Expression of
HLA-DR antigen and smooth muscle cell diﬀerentiation
markers by valvular ﬁbroblasts in degenerative aortic steno-
sis,” Journal of the American College of Cardiology, vol. 24, no.
7, pp. 1664–1671, 1994.
[57] J. J. Kaden, C. E. Dempﬂe, R. Grobholz et al., “Interleukin-1
beta promotes matrix metalloproteinase expression and cell
proliferation in calciﬁc aortic valve stenosis,” Atherosclerosis,
vol. 170, no. 2, pp. 205–211, 2003.
[58] J. J. Kaden, C.-E. Dempﬂe, R. Grobholz et al., “Inﬂammatory
regulation of extracellular matrix remodeling in calciﬁc
aortic valve stenosis,” Cardiovascular Pathology, vol. 14, no.
2, pp. 80–87, 2005.
[59] B. Jian, N. Narula, Q. Y. Li, E. R. Mohler, and R. J. Levy,
“Progression of aortic valve stenosis: TGF-β1i sp r e s e n t
in calciﬁed aortic valve cusps and promotes aortic valve
interstitial cell calciﬁcation via apoptosis,” Annals of Thoracic
Surgery, vol. 75, no. 2, pp. 457–465, 2003.
[60] R. G. Tompkins, J. J. Schnitzer, and M. L. Yarmush,
“Macromolecular transport within heart valves,” Circulation
Research, vol. 64, no. 6, pp. 1213–1223, 1989.
[61] D.Mohty,P.Pibarot,J.-P.Despr´ esetal.,“Associationbetween
plasma LDL particle size, valvular accumulation of oxidized
LDL, and inﬂammation in patients with aortic stenosis,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no.
1, pp. 187–193, 2008.
[62] M. R. Mehrabi, H. Sinzinger, C. Ekmekcioglu et al., “Accu-
mulation of oxidized LDL in human semilunar valves corre-
lates with coronary atherosclerosis,” Cardiovascular Research,
vol. 45, no. 4, pp. 874–882, 2000.
[63] C. Cˆ ot´ e, P. Pibarot, J. P. Despr´ es et al., “Association between
circulating oxidised low-density lipoprotein and ﬁbrocalciﬁc
remodelling of the aortic valve in aortic stenosis,” Heart, vol.
94, no. 9, pp. 1175–1180, 2008.
[64] K. D. O’Brien, D. M. Shavelle, M. T. Caulﬁeld et al.,
“Association of angiotensin-converting enzyme with low-
density lipoprotein in aortic valvular lesions and in human
plasma,” Circulation, vol. 106, no. 17, pp. 2224–2230, 2002.
[65] K. D. O’Brien, “Pathogenesis of calciﬁc aortic valve disease:
a disease process comes of age (and a good deal more),”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no.
8, pp. 1721–1728, 2006.
[66] L. Osman, M. H. Yacoub, N. Latif, M. Amrani, and A.
H. Chester, “Role of human valve interstitial cells in valve
calciﬁcation and their response to atorvastatin,” Circulation,
vol. 114, no. 1, pp. I547–I552, 2006.
[67] J. J. Kaden, R. Kilic ¸,A.Sarikoc ¸ et al., “Tumor necrosis factor
alpha promotes an osteoblast-like phenotype in human aor-
tic valve myoﬁbroblasts: a potential regulatory mechanism
of valvular calciﬁcation,” International Journal of Molecular
Medicine, vol. 16, no. 5, pp. 869–872, 2005.
[68] A. N. Babu, X. Meng, N. Zou et al., “Lipopolysaccharide
stimulation of human aortic valve interstitial cells activates
inﬂammation and osteogenesis,” Annals of Thoracic Surgery,
vol. 86, no. 1, pp. 71–76, 2008.
[69] X. Meng, L. Ao, Y. Song et al., “Expression of functional Toll-
like receptors 2 and 4 in human aortic valve interstitial cells:
potential roles in aortic valve inﬂammation and stenosis,”10 International Journal of Inﬂammation
American Journal of Physiology, vol. 294, no. 1, pp. C29–C35,
2008.
[70] J. H. Lee, X. Meng, M. J. Weyant, T. B. Reece, J. C. Cleveland
Jr., and D. A. Fullerton, “Stenotic aortic valves have dys-
functional mechanisms of anti-inﬂammation: implications
for aortic stenosis,” Journal of Thoracic and Cardiovascular
Surgery, vol. 141, no. 2, pp. 481–486, 2011.
[71] E. Rabkin, M. Aikawa, J. R. Stone, Y. Fukumoto, P. Libby,
andF.J.Schoen,“Activatedinterstitialmyoﬁbroblastsexpress
catabolic enzymes and mediate matrix remodeling in myxo-
matous heart valves,” Circulation, vol. 104, no. 21, pp. 2525–
2532, 2001.
[72] K. Tamura, M. Jones, I. Yamada, and V. J. Ferrans, “Wound
healing in the mitral valve,” Journal of Heart Valve Disease,
vol. 9, no. 1, pp. 53–63, 2000.
[73] C. Y. Y. Yip, J. H. Chen, R. Zhao, and C. A. Simmons, “Cal-
ciﬁcation by valve interstitial cells is regulated by the stiﬀness
of the extracellular matrix,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 29, no. 6, pp. 936–942, 2009.
[74] E.Aikawa,M.Nahrendorf,D.Sosnoviketal.,“Multimodality
molecular imaging identiﬁes proteolytic and osteogenic
activities in early aortic valve disease,” Circulation, vol. 115,
no. 3, pp. 377–386, 2007.
[75] E. Aikawa, M. Aikawa, P. Libby et al., “Arterial and aortic
valve calciﬁcation abolished by elastolytic cathepsin S deﬁ-
ciency in chronic renal disease,” Circulation, vol. 119, no. 13,
pp. 1785–1794, 2009.
[76] S.A.Dreger,P.M.Taylor,S.P.Allen,andM.H.Yacoub,“Pro-
ﬁle and localization of matrix metalloproteinases (MMPs)
and their tissue inhibitors (TIMPs) in human heart valves,”
Journal of Heart Valve Disease, vol. 11, no. 6, pp. 875–880,
2002.
[77] J. Wahlgren, P. Maisi, T. Sorsa et al., “Expression of MMP2,
MMP9, MTI-MMP, TIMP1, and TIMP2 mRNA in valvular
lesions of the heart,” The Journal of Pathology, vol. 194, no. 2,
pp. 225–231, 2001.
[78] S. Helske, S. Syv¨ aranta, K. A. Lindstedt et al., “Increased
expression of elastolytic cathepsins S, K, and V and their
inhibitor cystatin C in stenotic aortic valves,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 26, no. 8, pp. 1791–
1798, 2006.
[79] S. Helske, S. Syv¨ aranta, M. Kupari et al., “Possible role for
mast cell-derived cathepsin G in the adverse remodelling of
stenotic aortic valves,” European Heart Journal, vol. 27, no.
12, pp. 1495–1504, 2006.
[ 8 0 ] W .D .M e r ry m a n ,H .D .L u k o ﬀ,R .A .L o n g ,G .C .E n g e l m a y r ,
R. A. Hopkins, and M. S. Sacks, “Synergistic eﬀects of cyclic
tension and transforming growth factor-β1 on the aortic
valve myoﬁbroblast,” Cardiovascular Pathology, vol. 16, no. 5,
pp. 268–276, 2007.
[ 8 1 ]A .P a g e - M c C a w ,A .J .E w a l d ,a n dZ .W e r b ,“ M a t r i xm e t a l l o -
proteinases and the regulation of tissue remodelling,” Nature
Reviews Molecular Cell Biology, vol. 8, no. 3, pp. 221–233,
2007.
[ 8 2 ]G .A .W a l k e r ,K .S .M a s t e r s ,D .N .S h a h ,K .S .A n s e t h ,
and L. A. Leinwand, “Valvular myoﬁbroblast activation by
transforming growth factor-β: implications for pathological
extracellular matrix remodeling in heart valve disease,”
Circulation Research, vol. 95, no. 3, pp. 253–260, 2004.
[83] J. N. Clark-Greuel, J. M. Connolly, E. Sorichillo et al.,
“Transforming growth factor-β1 mechanisms in aortic valve
calciﬁcation: increased alkaline phosphatase and related
events,” Annals of Thoracic Surgery, vol. 83, no. 3, pp. 946–
953, 2007.
[84] O. Fondard, D. Detaint, B. Iung et al., “Extracellular matrix
remodelling in human aortic valve disease: the role of matrix
metalloproteinases and their tissue inhibitors,” European
Heart Journal, vol. 26, no. 13, pp. 1333–1341, 2005.
[85] R. B. Hinton and K. E. Yutzey, “Heart valve structure and
function in development and disease,” Annual Review of
Physiology, vol. 73, pp. 29–46, 2011.
[86] R. B. Hinton, J. Lincoln, G. H. Deutsch et al., “Extracellular
matrix remodeling and organization in developing and
diseased aortic valves,” Circulation Research, vol. 98, no. 11,
pp. 1431–1438, 2006.
[87] F. J. Schoen, “Cardiac valves and valvular pathology: update
on function, disease, repair, and replacement,” Cardiovascu-
lar Pathology, vol. 14, no. 4, pp. 189–194, 2005.
[88] R. B. Guthrie and J. E. Edwards, “Pathology of the
myxomatous mitral value. Nature, secondary changes and
complications,” Minnesota Medicine, vol. 59, no. 9, pp. 637–
647, 1976.
[89] M. J. Davies, B. P. Moore, and M. V. Braimbridge, “The
ﬂoppy mitral valve. Study of incidence, pathology, and
complications in surgical, necropsy and forensic material,”
British Heart Journal, vol. 40, no. 5, pp. 468–481, 1978.
[90] L. A. Freed, D. Levy, R. A. Levine et al., “Prevalence and
clinical outcome of mitral-valve prolapse,” The New England
Journal of Medicine, vol. 341, no. 1, pp. 1–7, 1999.
[91] A. D. Durbin and A. I. Gotlieb, “Advances towards under-
standing heart valve response to injury,” Cardiovascular
Pathology, vol. 11, no. 2, pp. 69–77, 2002.
[92] H. C. Dietz, G. R. Cutting, R. E. Pyeritz et al., “Marfan
syndrome caused by a recurrent de novo missense mutation
in the ﬁbrillin gene,” Nature, vol. 352, no. 6333, pp. 337–339,
1991.
[93] A. K. Ewart, C. A. Morris, D. Atkinson et al., “Hemizygosity
at the elastin locus in a developmental disorder, Williams
syndrome,” Nature Genetics, vol. 5, no. 1, pp. 11–16, 1993.
[94] T. Pihlajaniemi, L. A. Dickson, F. M. Pope et al., “Osteoge-
nesis imperfecta: cloning of a pro-α2(I) collagen gene with
a frameshift mutation,” Journal of Biological Chemistry, vol.
259, no. 21, pp. 12941–12944, 1984.
[ 9 5 ] R .S .W o n g ,F .M .F o l l i s ,B .K .S h i v e l y ,a n dJ .A .
Wernly, “Osteogenesis imperfecta and cardiovascular dis-
eases,” Annals of Thoracic Surgery, vol. 60, no. 5, pp. 1439–
1443, 1995.
[96] G. H. Burch, Y. Gong, W. Liu et al., “Tenascin-X deﬁciency
is associated with Ehlers-Danlos syndrome,” Nature Genetics,
vol. 17, no. 1, pp. 104–108, 1997.
[97] N. P. Burrows, A. C. Nicholls, J. R. W. Yates et al., “The
gene encoding collagen α1(V) (COL5A1) is linked to mixed
Ehlers-Danlos syndrome type I/II,” J o u r n a lo fI n v e s t i g a t i v e
Dermatology, vol. 106, no. 6, pp. 1273–1276, 1996.
[98] F. Malfait, S. Symoens, P. Coucke, L. Nunes, S. De Almeida,
a n dA .D eP a e p e ,“ T o t a la b s e n c eo ft h ea l p h a 2 ( I )c h a i n
of collagen type I causes a rare form of Ehlers-Danlos
syndrome with hypermobility and propensity to cardiac
valvular problems,” Journal of Medical Genetics, vol. 43, no.
7, p. e36, 2006.
[99] S. Annunen, J. K¨ orkk¨ o, M. Czarny et al., “Splicing mutations
of 54-bp exons in the COL11A1 gene cause Marshall
syndrome, but other mutations cause overlapping Mar-
shall/Stickler phenotypes,” The American Journal of Human
Genetics, vol. 65, no. 4, pp. 974–983, 1999.
[100] R. M. Liberfarb and A. Goldblatt, “Prevalence of mitral
valve prolapse in the Stickler syndrome,” American Journal
of Medical Genetics, vol. 24, no. 3, pp. 387–392, 1986.International Journal of Inﬂammation 11
[101] C. M. Ng, A. Cheng, L. A. Myers et al., “TGF-β-dependent
pathogenesis of mitral valve prolapse in a mouse model of
Marfan syndrome,” The Journal of Clinical Investigation, vol.
114, no. 11, pp. 1586–1592, 2004.
[102] S. L. Dallas, K. Miyazono, T. M. Skerry, G. R. Mundy, and L.
F. Bonewald, “Dual role for the latent transforming growth
factor-β binding protein in storage of latent TGF-β in the
extracellular matrix and as a structural matrix protein,”
Journal of Cell Biology, vol. 131, no. 2, pp. 539–549, 1995.
[103] Z. Isogai, R. N. Ono, S. Ushiro et al., “Latent transforming
growth factor β-binding protein 1 interacts with ﬁbrillin
and is a microﬁbril-associated protein,” Journal of Biological
Chemistry, vol. 278, no. 4, pp. 2750–2757, 2003.
[104] J. P. Habashi, D. P. Judge, T. M. Holm et al., “Losartan, an
AT1 antagonist, prevents aortic aneurysm in a mouse model
of Marfan syndrome,” Science, vol. 312, no. 5770, pp. 117–
121, 2006.
[105] B. S. Brooke, J. P. Habashi, D. P. Judge, N. Patel, B. Loeys, and
H.C.Dietz,“AngiotensinIIblockadeandaortic-rootdilation
inmarfan’ssyndrome,”TheNewEnglandJournalofMedicine,
vol. 358, no. 26, pp. 2787–2795, 2008.
[106] M. O. E. Hil´ a r i oa n dM .T .S .L .R .A .T e r r e r i ,“ R h e u m a t i c
fever and post-streptococcal arthritis,” Best Practice and
Research: Clinical Rheumatology, vol. 16, no. 3, pp. 481–494,
2002.
[107] A. Grover, A. Dhawan, S. D. Iyengar, I. S. Anand, P. L. Wahi,
and N. K. Ganguly, “Epidemiology of rheumatic fever and
rheumatic heart disease in a rural community in northern
India,” Bulletin of the World Health Organization, vol. 71, no.
1, pp. 59–66, 1993.
[108] J. P. Veinot, “Pathology of inﬂammatory native valvular heart
disease,” Cardiovascular Pathology, vol. 15, no. 5, pp. 243–
251, 2006.
[109] C. H. da Silva, “Rheumatic fever: a multicenter study in the
stateofS˜ aoPaulo.PediatricCommittee—S˜ aoPauloPediatric
Rheumatology Society,” Revista do Hospital das Cl´ ınicas, vol.
54, no. 3, pp. 85–90, 1999.
[110] E. Rullan and L. H. Sigal, “Rheumatic fever,” Current
Rheumatology Reports, vol. 3, no. 5, pp. 445–452, 2001.
[111] V. A. Fischetti, “Streptococcal M protein,” Scientiﬁc Ameri-
can, vol. 264, no. 6, pp. 58–65, 1991.
[112] M. R. Wessels, A. E. Moses, J. B. Goldberg, and T. J. DiCesare,
“Hyaluronic acid capsule is a virulence factor for mucoid
group A streptococci,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 88, no. 19, pp.
8317–8321, 1991.
[113] M. R. Wessels, J. B. Goldberg, A. E. Moses, and T. J. DiCesare,
“Eﬀects on virulence of mutations in a locus essential for
hyaluronic acid capsule expression in group A streptococci,”
Infection and Immunity, vol. 62, no. 2, pp. 433–441, 1994.
[114] J. B. Dale, R. G. Washburn, M. B. Marques, and M. R.
Wessels, “Hyaluronate capsule and surface M protein in
resistance to opsonization of group A streptococci,” Infection
and Immunity, vol. 64, no. 5, pp. 1495–1501, 1996.
[115] A. Bhatnagar, A. Grover, and N. K. Ganguly, “Superantigen-
induced T cell responses in acute rheumatic fever and
chronic: rheumatic heart disease patients,” Clinical and
ExperimentalImmunology,vol.116,no.1,pp.100–106,1999.
[116] V. Pancholi and V. A. Fischetti, “Isolation and characteriza-
tionofthecell-associatedregionofgroupAstreptococcalM6
protein,” Journal of Bacteriology, vol. 170, no. 6, pp. 2618–
2624, 1988.
[117] V. A. Fischetti, “Streptococcal M protein: molecular design
a n db i o l o g i c a lb e h a v i o r , ”Clinical Microbiology Reviews, vol.
2, no. 3, pp. 285–314, 1989.
[118] M. W. Cunningham, “T cell mimicry in inﬂammatory heart
disease,” Molecular Immunology, vol. 40, no. 14-15, pp. 1121–
1127, 2004.
[119] J.E.Galvin,M.E.Hemric,K.Ward,andM.W.Cunningham,
“Cytotoxic mAb from rheumatic carditis recognizes heart
valves and laminin,” The Journal of Clinical Investigation, vol.
106, no. 2, pp. 217–224, 2000.
[120] S. Roberts, S. Kosanke, S. T. Dunn, D. Jankelow, C. M. G.
Duran,andM.W.Cunningham,“Pathogenicmechanismsin
rheumatic carditis: focus on valvular endothelium,” Journal
of Infectious Diseases, vol. 183, no. 3, pp. 507–511, 2001.
[121] E. Mylonakis and S. B. Calderwood, “Infective endocarditis
in adults,” The New England Journal of Medicine, vol. 345, no.
18, pp. 1318–1330, 2001.
[122] W. Wilson, K. A. Taubert, M. Gewitz et al., “Prevention of
infective endocarditis: guidelines from the American Heart
Association,” Circulation, vol. 116, no. 15, pp. 1736–1754,
2007.
[123] P. Moreillon and Y. A. Que, “Infective endocarditis,” The
Lancet, vol. 363, no. 9403, pp. 139–149, 2004.
[124] M. H. A. M. Veltrop, M. J. L. M. F. Bancsi, R. M. Bertina, and
J. Thompson, “Role of monocytes in experimental Staphylo-
coccus aureus endocarditis,” Infection and Immunity, vol. 68,
no. 8, pp. 4818–4821, 2000.
[125] M. E. Hemler, M. J. Elices, C. Parker, and Y. Takada,
“Structure of the integrin VLA-4 and its cell-cell and cell-
matrix adhesion functions,” Immunological Reviews, no. 114,
pp. 45–65, 1990.
[126] B. Sinha, P. Francois, Y. A. Que et al., “Heterologously
expressed staphylococcus aureus ﬁbronectin-binding pro-
teins are suﬃcient for invasion of host cells,” Infection and
Immunity, vol. 68, no. 12, pp. 6871–6878, 2000.
[127] B. D. Prendergast, “The changing face of infective endocardi-
tis,” Heart, vol. 92, no. 7, pp. 879–885, 2006.
[128] B. L. Roth, “Focus on research: drugs and valvular heart
disease,” The New England Journal of Medicine, vol. 356, no.
1, pp. 6–9, 2007.
[129] R. Schade, F. Andersohn, S. Suissa, W. Haverkamp, and E.
Garbe, “Dopamine agonists and the risk of cardiac-valve
regurgitation,” The New England Journal of Medicine, vol.
356, no. 1, pp. 29–38, 2007.
[130] V. Setola, S. J. Hufeisen, K. J. Grande-Allen et al., “3,4-
methylenedioxymethamphetamine (MDMA, “Ecstasy”)
induces fenﬂuramine-like proliferative actions on human
cardiac valvular interstitial cells in vitro,” Molecular
Pharmacology, vol. 63, no. 6, pp. 1223–1229, 2003.
[131] B. I. Gustafsson, O. Hauso, I. Drozdov, M. Kidd, and I. M.
Modlin, “Carcinoid heart disease,” International Journal of
Cardiology, vol. 129, no. 3, pp. 318–324, 2008.
[132] B.I.Gustafsson,K.Tømmer˚ as,I.Nordrumetal.,“Long-term
serotonin administration induces heart valve disease in rats,”
Circulation, vol. 111, no. 12, pp. 1517–1522, 2005.
[133] N. M. Rajamannan, N. Caplice, F. Anthikad et al., “Cell
proliferation in carcinoid valve disease: a mechanism for
serotonin eﬀects,” J o u r n a lo fH e a r tV a l v eD i s e a s e , vol. 10, no.
6, pp. 827–831, 2001.
[134] B. Jian, J. Xu, J. Connolly et al., “Serotonin mechanisms
in heart valve disease I: serotonin-induced up-regulation of
transforming growth factor-β1 via G-protein signal trans-
duction in aortic valve interstitial cells,” American Journal of
Pathology, vol. 161, no. 6, pp. 2111–2121, 2002.12 International Journal of Inﬂammation
[135] J. M. Connolly, M. A. Bakay, J. T. Fulmer et al., “Fenﬂu-
ramine disrupts the mitral valve interstitial cell response to
serotonin,” American Journal of Pathology, vol. 175, no. 3, pp.
988–997, 2009.
[136] S. Disatian and E. C. Orton, “Autocrine serotonin and trans-
forminggrowthfactorbeta1signalingmediatesspontaneous
myxomatous mitral valve disease,” The Journal of Heart Valve
Disease, vol. 18, no. 1, pp. 44–51, 2009.
[137] I. El-Hamamsy, K. Balachandran, M. H. Yacoub et al.,
“Endothelium-dependent regulation of the mechanical
properties of aortic valve cusps,” Journal of the American
College of Cardiology, vol. 53, no. 16, pp. 1448–1455, 2009.
[138] A. H. Chester, M. Misfeld, H. H. Sievers, and M. H.
Yacoub, “Inﬂuence of 5-hydroxytryptamine on aortic valve
competence in vitro,” Journal of Heart Valve Disease, vol. 10,
no. 6, pp. 822–826, 2001.
[139] N. G. Singer and A. I. Caplan, “Mesenchymal stem cells:
mechanisms of inﬂammation,” Annual Review of Pathology:
Mechanisms of Disease, vol. 6, pp. 457–478, 2011.
[140] A. Deb, S. H. Wang, K. Skelding, D. Miller, D. Simper, and N.
Caplice,“Bonemarrow-derivedmyoﬁbroblastsarepresentin
adulthumanheartvalves,”JournalofHeartValveDisease,vol.
14, no. 5, pp. 674–678, 2005.
[141] R. P. Visconti, Y. Ebihara, A. C. LaRue et al., “An in vivo
analysis of hematopoietic stem cell potential: hematopoietic
origin of cardiac valve interstitial cells,” Circulation Research,
vol. 98, no. 5, pp. 690–696, 2006.
[142] Y. Wu, J. E. Ip, J. Huang et al., “Essential role of ICAM-
1/CD18 in mediating EPC recruitment, angiogenesis, and
repair to the infarcted myocardium,” Circulation Research,
vol. 99, no. 3, pp. 315–322, 2006.
[143] T. Karamlou, K. Jang, W. G. Williams et al., “Outcomes and
associated risk factors for aortic valve replacement in 160
children: a competing-risks analysis,” Circulation, vol. 112,
no. 22, pp. 3462–3469, 2005.
[144] M. H. Yacoub and J. J.M. Takkenberg, “Will heart valve tissue
engineering change the world?” Nature Clinical Practice
Cardiovascular Medicine, vol. 2, no. 2, pp. 60–61, 2005.
[145] I. Vesely, “Heart valve tissue engineering,” Circulation
Research, vol. 97, no. 8, pp. 743–755, 2005.
[146] S. L. Hilbert, R. Yanagida, J. Souza et al., “Prototype anionic
detergent technique used to decellularize allograft valve
conduits evaluated in the right ventricular outﬂow tract in
sheep,” The Journal of Heart Valve Disease, vol. 13, no. 5, pp.
831–840, 2004.
[147] F. Opitz, K. Schenke-Layland, T. U. Cohnert et al., “Tissue
engineering of aortic tissue: dire consequence of suboptimal
elastic ﬁber synthesis in vivo,” Cardiovascular Research, vol.
63, no. 4, pp. 719–730, 2004.
[148] T. Konuma, E. J. Devaney, E. L. Bove et al., “Performance of
CryoValve SG decellularized pulmonary allografts compared
with standard cryopreserved allografts,” Annals of Thoracic
Surgery, vol. 88, no. 3, pp. 849–855, 2009.
[149] P. Simon, M. T. Kasimir, G. Seebacher et al., “Early failure of
the tissue engineered porcine heart valve SYNERGRAFTTM
in pediatric patients,” European Journal of Cardio-Thoracic
Surgery, vol. 23, no. 6, pp. 1002–1006, 2003.
[150] I. Cicha, A. R¨ uﬀer, R. Cesnjevar et al., “Early obstruction of
decellularized xenogenic valves in pediatric patients: involve-
ment of inﬂammatory and ﬁbroproliferative processes,”
Cardiovascular Pathology, vol. 20, no. 4, pp. 222–231, 2011.
[151] A. Bayrak, M. Tyralla, J. Ladhoﬀ et al., “Human immune
responses to porcine xenogeneic matrices and their extracel-
lular matrix constituents in vitro,” Biomaterials, vol. 31, no.
14, pp. 3793–3803, 2010.
[152] F. W. H. Sutherland, T. E. Perry, Y. Yu et al., “From stem cells
to viable autologous semilunar heart valve,” Circulation, vol.
111, no. 21, pp. 2783–2791, 2005.
[153] A. D. Person, S. E. Klewer, R. B. Runyan, and W. J. Kwang,
International Review of Cytology 287, Academic Press, New
York, NY, USA, 2005.
[154] E. L. Krug, R. B. Runyan, and R. R. Markwald, “Pro-
tein extracts from early embryonic hearts initiate cardiac
endothelial cytodiﬀerentiation,” Developmental Biology, vol.
112, no. 2, pp. 414–426, 1985.
[155] F. J. Manasek, “Sulfated extracellular matrix production
in the embryonic heart and adjacent tissues,” Journal of
Experimental Zoology, vol. 174, no. 4, pp. 415–439, 1970.
[156] F. J. Manasek, M. Reid, W. Vinson, J. Seyer, and R. Johnson,
“Gycosaminoglycan synthesis by the early embryonic chick
heart,” Developmental Biology, vol. 35, no. 2, pp. 332–348,
1973.
[157] R. R. Markwald, T. P. Fitzharris, and F. J. Manasek,
“Structural development of endocardial cushions,” American
Journal of Anatomy, vol. 148, no. 1, pp. 85–119, 1977.
[158] V. Hamburger and H. L. Hamilton, “A series of normal
stages in the development of the chick embryo. 1951,”
Developmental Dynamics, vol. 195, no. 4, pp. 231–272, 1992.
[159] A. R. Sinning and C. C. Hewitt, “Identiﬁcation of a 283-kDa
protein component of the particulate matrix associated with
c a r d i a cm e s e n c h y m ef o r m a t i o n , ”Acta Anatomica, vol. 155,
no. 4, pp. 219–230, 1996.
[160] A. M. Wunsch, C. D. Little, and R. R. Markwald, “Cardiac
endothelial heterogeneity deﬁnes valvular development as
demonstrated by the diverse expression of JB3, an antigen of
the endocardial cushion tissue,” Developmental Biology, vol.
165, no. 2, pp. 585–601, 1994.
[161] A. F. Ramsdell and R. R. Markwald, “Induction of endocar-
dial cushion tissue in the avian heart is regulated, in part,
by TGFβ-3-mediated autocrine signaling,” Developmental
Biology, vol. 188, no. 1, pp. 64–74, 1997.
[162] D. H. Bernanke and R. R. Markwald, “Migratory behavior
of cardiac cushion tissue cells in a collagen-lattice culture
system,” Developmental Biology, vol. 91, no. 2, pp. 235–245,
1982.
[163] Y. Nakajima, V. Mironov, T. Yamagishi, H. Nakamura, and
R. R. Markwald, “Expression of smooth muscle alpha-actin
in mesenchymal cells during formation of avian endocardial
cushion tissue: a role for transforming growth factor β3,”
Developmental Dynamics, vol. 209, no. 3, pp. 296–309, 1997.
[164] A. K. Nath, R. M. Brown, M. Michaud, M. R. Sierra-
Honigmann, M. Snyder, and J. A. Madri, “Leptin aﬀects
endocardial cushion formation by modulating EMT and
migration via Akt signaling cascades,” Journal of Cell Biology,
vol. 181, no. 2, pp. 367–380, 2008.
[165] S. S. Mou, S. B. Haudek, L. Lequier et al., “Myocardial
inﬂammatory activation in children with congenital heart
disease,” Critical Care Medicine, vol. 30, no. 4, pp. 827–832,
2002.
[166] M. Qing, K. Schumacher, R. Heise et al., “Intramyocardial
synthesis of pro- and anti-inﬂammatory cytokines in infants
with congenital cardiac defects,” Journal of the American
College of Cardiology, vol. 41, no. 12, pp. 2266–2274, 2003.
[167] E. Appachi, E. Mossad, R. B. B. Mee, and P. Bokesch, “Peri-
operative serum interleukins in neonates with hypoplastic
left-heart syndrome and transposition of the great arteries,”
Journal of Cardiothoracic and Vascular Anesthesia, vol. 21, no.
2, pp. 184–190, 2007.International Journal of Inﬂammation 13
[168] L.Kwee,H.S.Baldwin,H.M.Shenetal.,“Defectivedevelop-
ment of the embryonic and extraembryonic circulatory sys-
tems in vascular cell adhesion molecule (VCAM-1) deﬁcient
mice,” Development, vol. 121, no. 2, pp. 489–503, 1995.
[169] C. E. Tseng and J. P. Buyon, “Neonatal lupus syndromes,”
Rheumatic Disease Clinics of North America, vol. 23, no. 1,
pp. 31–54, 1997.
[170] A. N. Krishnan, C. A. Sable, and M. T. Donofrio, “Spectrum
of fetal echocardiographic ﬁndings in fetuses of women with
clinical or serologic evidence of systemic lupus erythemato-
sus,” Journal of Maternal-Fetal and Neonatal Medicine, vol.
21, no. 11, pp. 776–782, 2008.
[171] J. P. Moak, K. S. Barron, T. J. Hougen et al., “Congenital
heart block: development of late-onset cardiomyopathy, a
previously underappreciated sequela,” Journal of the Ameri-
can College of Cardiology, vol. 37, no. 1, pp. 238–242, 2001.
[172] J. P. Buyon and R. Winchester, “Congenital complete heart
block. A human model of passively acquired autoimmune
injury,”ArthritisandRheumatism,vol.33,no.5,pp.609–614,
1990.
[173] J. P. Buyon, R. Hiebert, J. Copel et al., “Autoimmune-
associated congenital heart block: demographics, mortality,
morbidity and recurrence rates obtained from a national
neonatal lupus registry,” Journal of the American College of
Cardiology, vol. 31, no. 7, pp. 1658–1666, 1998.
[174] S. Rounioja, J. R¨ as¨ a n e n ,V .G l u m o ﬀ,M .O j a n i e m i ,K .
M¨ akikallio, and M. Hallman, “Intra-amniotic lipopolysac-
charide leads to fetal cardiac dysfunction: a mouse model for
fetal inﬂammatory response,” Cardiovascular Research, vol.
60, no. 1, pp. 156–164, 2003.
[175] S. Rounioja, J. R¨ as¨ a n e n ,M .O j a n i e m i ,V .G l u m o ﬀ,H .
Autio-Harmainen, and M. Hallman, “Mechanism of acute
fetal cardiovascular depression after maternal inﬂammatory
challenge in mouse,” American Journal of Pathology, vol. 166,
no. 6, pp. 1585–1592, 2005.
[176] S. Hern´ andez-Gutierrez, I. Garc´ ıa-Pel´ aez, A. Zentella-Dehesa
etal.,“NF-κBsignalingblockadebyBay11-7085duringearly
cardiac morphogenesis induces alterations of the outﬂow
tract in chicken heart,” Apoptosis, vol. 11, no. 7, pp. 1101–
1109, 2006.
[177] A. M. Ranger, M. J. Grusby, M. R. Hodge et al., “The
transcription factor NF-ATc is essential for cardiac valve
formation,” Nature, vol. 392, no. 6672, pp. 186–190, 1998.
[178] R. Sharma, A. P. Bolger, W. Li et al., “Elevated circulating
levels of inﬂammatory cytokines and bacterial endotoxin in
adults with congenital heart disease,” The American Journal
of Cardiology, vol. 92, no. 2, pp. 188–193, 2003.